Extended dosing of monoclonal antibodies in multiple sclerosis

被引：30

作者：

Kempen, Zoe L. E. van ^{[1
]}

Toorop, Alyssa A. ^{[1
]}

Sellebjerg, Finn ^{[2
]}

Giovannoni, Gavin ^{[3
]}

Killestein, Joep ^{[1
]}

机构：

[1] Univ Amsterdam, MS Ctr Amsterdam, Locat VUMC, Med Ctr, Boelelaan 1118, NL-1081 HZ Amsterdam, Netherlands

[2] Copenhagen Univ Hosp, Danish Multiple Sclerosis Ctr, Copenhagen, Denmark

[3] Barts & London Queen Marys Sch Med & Dent, London, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 13期

关键词：

Multiple sclerosis; monoclonal antibodies; extended dosing; personalized dosing; INTERFERON BETA-1A; CONTROLLED TRIAL; NATALIZUMAB; RITUXIMAB; PLACEBO; SAFETY; OCRELIZUMAB; OFATUMUMAB; POPULATION; EFFICACY;

D O I：

10.1177/13524585211065711

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, "no evidence of MS disease activity" is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-alpha(4)beta(1)-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.

引用

页码：2001 / 2009

页数：9

共 50 条

[1] Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies [J].

Achiron, Anat ;

Mandel, Mathilda ;

Dreyer-Alster, Sapir ;

Harari, Gil ;

Magalashvili, David ;

Sonis, Polina ;

Dolev, Mark ;

Menascu, Shay ;

Flechter, Shlomo ;

Falb, Rina ;

Gurevich, Michael .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14

[2] The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis [J].

Baker, David ;

Pryce, Gareth ;

James, Louisa K. ;

Marta, Monica ;

Schmierer, Klaus .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 44

[3] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial [J].

Bar-Or, Amit ;

Calabresi, Peter A. J. ;

Arnlod, Douglas ;

Markowitz, Clyde ;

Shafer, Stuart ;

Kasper, Lloyd H. ;

Waubant, Ernmanuelle ;

Gazda, Suzanne ;

Fox, Robert J. ;

Panzara, Michael ;

Sarkar, Neena ;

Agarwal, Sunil ;

Smith, Craig H. .

ANNALS OF NEUROLOGY, 2008, 63 (03) :395-400

[4] Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study [J].

Bar-Or, Amit ;

Calkwood, Jonathan C. ;

Chognot, Cathy ;

Evershed, Joanna ;

Fox, Edward J. ;

Herman, Ann ;

Manfrini, Marianna ;

McNamara, John ;

Robertson, Derrick S. ;

Stokmaier, Daniela ;

Wendt, Jeanette K. ;

Winthrop, Kevin L. ;

Traboulsee, Anthony .

NEUROLOGY, 2020, 95 (14) :E1999-E2008

[5] Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study [J].

Bar-Or, Amit ;

Grove, Richard A. ;

Austin, Daren J. ;

Tolson, Jerry M. ;

VanMeter, Susan A. ;

Lewis, Eric W. ;

Derosier, Frederick J. ;

Lopez, Monica C. ;

Kavanagh, Sarah T. ;

Miller, Aaron E. ;

Sorensen, Per S. .

NEUROLOGY, 2018, 90 (20) :E1805-E1814

[6] Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness [J].

Barun, Barbara ;

Gabelic, Tereza ;

Adamec, Ivan ;

Babic, Antonija ;

Lalic, Hrvoje ;

Batinic, Drago ;

Skoric, Magdalena Krbot ;

Habek, Mario .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48

[7] Extended interval dosing of natalizumab: a two-center, 7-year experience [J].

Bomprezzi, Roberto ;

Pawate, Siddharama .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2014, 7 (05) :227-231

[8] Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis [J].

Boremalm, Malin ;

Sundstrom, Peter ;

Salzer, Jonatan .

JOURNAL OF NEUROLOGY, 2021, 268 (06) :2161-2168

[9] Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis [J].

Chisari, Clara Grazia ;

Grimaldi, Luigi Maria ;

Salemi, Giuseppe ;

Ragonese, Paolo ;

Iaffaldano, Pietro ;

Bonavita, Simona ;

Sparaco, Maddalena ;

Rovaris, Marco ;

D'Arma, Alessia ;

Lugaresi, Alessandra ;

Ferro, Maria Teresa ;

Grossi, Paola ;

Di Sapio, Alessia ;

Cocco, Eleonora ;

Granella, Franco ;

Curti, Erica ;

Lepore, Vito ;

Trojano, Maria ;

Patti, Francesco .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (12) :1297-1303

[10] Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? [J].

Clerico, Marinella ;

De Mercanti, Stefania Federica ;

Signori, Alessio ;

Iudicello, Marco ;

Cordioli, Cinzia ;

Signoriello, Elisabetta ;

Lus, Giacomo ;

Bonavita, Simona ;

Lavorgna, Luigi ;

Maniscalco, Giorgia Teresa ;

Curti, Erica ;

Lorefice, Lorena ;

Cocco, Eleonora ;

Nociti, Viviana ;

Mirabella, Massimiliano ;

Baroncini, Damiano ;

Mataluni, Giorgia ;

Landi, Doriana ;

Petruzzo, Martina ;

Lanzillo, Roberta ;

Gandoglia, Ilaria ;

Laroni, Alice ;

Frangiamore, Rita ;

Sartori, Arianna ;

Cavalla, Paola ;

Costantini, Gianfranco ;

Sormani, Maria Pia ;

Capra, Ruggero .

NEUROTHERAPEUTICS, 2020, 17 (01) :200-207

← 1 2 3 4 5 →